Somatostatin imaging of neuroendocrine-differentiated prostate cancer

Thomas A. Hope; Rahul Aggarwal; Jeff P. Simko; Henry F. Vanbrocklin; Charles J. Ryan

doi:10.1097/RLU.0000000000000776

Somatostatin imaging of neuroendocrine-differentiated prostate cancer

Thomas A. Hope, Rahul Aggarwal, Jeff P. Simko, Henry F. Vanbrocklin, Charles J. Ryan

Pediatrics - Administration

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

After prolonged androgen deprivation therapy, a subset of castrate-resistant prostate cancer patients will develop neuroendocrine prostate cancer (NEPC) associated with resistance to further hormonal therapy and frequent visceral metastases. Imaging the presence of somatostatin receptors on the cancer cell surface may provide a readily available, noninvasive means to distinguish adenocarcinoma from NEPC. This distinction is important for therapeutic decision making and may open the door for developing novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. We describe a case of NEPC successfully imaged using ¹¹¹In-labeled octreotide.

Original language	English (US)
Pages (from-to)	540-541
Number of pages	2
Journal	Clinical nuclear medicine
Volume	40
Issue number	6
DOIs	https://doi.org/10.1097/RLU.0000000000000776
State	Published - Jun 25 2015

Bibliographical note

Publisher Copyright:
© 2015 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

FDG
neuroendocrine
octreotide
prostate cancer
somatostatin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1097/RLU.0000000000000776

OpenUrl availability

Full text

Cite this

@article{f715b2f66fae4c69831dbd9a475d7b8a,

title = "Somatostatin imaging of neuroendocrine-differentiated prostate cancer",

abstract = "After prolonged androgen deprivation therapy, a subset of castrate-resistant prostate cancer patients will develop neuroendocrine prostate cancer (NEPC) associated with resistance to further hormonal therapy and frequent visceral metastases. Imaging the presence of somatostatin receptors on the cancer cell surface may provide a readily available, noninvasive means to distinguish adenocarcinoma from NEPC. This distinction is important for therapeutic decision making and may open the door for developing novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. We describe a case of NEPC successfully imaged using 111In-labeled octreotide.",

keywords = "FDG, neuroendocrine, octreotide, prostate cancer, somatostatin",

author = "Hope, {Thomas A.} and Rahul Aggarwal and Simko, {Jeff P.} and Vanbrocklin, {Henry F.} and Ryan, {Charles J.}",

year = "2015",

month = jun,

day = "25",

doi = "10.1097/RLU.0000000000000776",

language = "English (US)",

volume = "40",

pages = "540--541",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Somatostatin imaging of neuroendocrine-differentiated prostate cancer

AU - Hope, Thomas A.

AU - Aggarwal, Rahul

AU - Simko, Jeff P.

AU - Vanbrocklin, Henry F.

AU - Ryan, Charles J.

PY - 2015/6/25

Y1 - 2015/6/25

N2 - After prolonged androgen deprivation therapy, a subset of castrate-resistant prostate cancer patients will develop neuroendocrine prostate cancer (NEPC) associated with resistance to further hormonal therapy and frequent visceral metastases. Imaging the presence of somatostatin receptors on the cancer cell surface may provide a readily available, noninvasive means to distinguish adenocarcinoma from NEPC. This distinction is important for therapeutic decision making and may open the door for developing novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. We describe a case of NEPC successfully imaged using 111In-labeled octreotide.

AB - After prolonged androgen deprivation therapy, a subset of castrate-resistant prostate cancer patients will develop neuroendocrine prostate cancer (NEPC) associated with resistance to further hormonal therapy and frequent visceral metastases. Imaging the presence of somatostatin receptors on the cancer cell surface may provide a readily available, noninvasive means to distinguish adenocarcinoma from NEPC. This distinction is important for therapeutic decision making and may open the door for developing novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. We describe a case of NEPC successfully imaged using 111In-labeled octreotide.

KW - FDG

KW - neuroendocrine

KW - octreotide

KW - prostate cancer

KW - somatostatin

UR - http://www.scopus.com/inward/record.url?scp=84929848945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929848945&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000000776

DO - 10.1097/RLU.0000000000000776

M3 - Article

C2 - 25783510

AN - SCOPUS:84929848945

SN - 0363-9762

VL - 40

SP - 540

EP - 541

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 6

ER -

Somatostatin imaging of neuroendocrine-differentiated prostate cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this